Compare EVTC & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVTC | AGIO |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2013 | 2013 |
| Metric | EVTC | AGIO |
|---|---|---|
| Price | $29.77 | $31.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $35.20 | ★ $46.00 |
| AVG Volume (30 Days) | 437.0K | ★ 914.3K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.67% | N/A |
| EPS Growth | ★ 27.17 | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $453,869,000.00 | $43,011,000.00 |
| Revenue This Year | $16.93 | $229.47 |
| Revenue Next Year | $8.30 | $94.99 |
| P/E Ratio | $63.15 | ★ N/A |
| Revenue Growth | ★ 11.48 | N/A |
| 52 Week Low | $21.81 | $22.24 |
| 52 Week High | $34.41 | $46.00 |
| Indicator | EVTC | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.41 | 40.06 |
| Support Level | $28.79 | $26.71 |
| Resistance Level | $30.23 | $35.77 |
| Average True Range (ATR) | 0.84 | 1.12 |
| MACD | 0.31 | -0.12 |
| Stochastic Oscillator | 92.38 | 17.29 |
Evertec Inc is a transaction processing business in Latin America and the Caribbean. Its business segments are Merchant Acquiring, Payment Services - Puerto Rico & Caribbean, Latin America Payments and Solutions, and Business Solutions. Latin America Payments and Solutions segment derive maximum revenue. The company serves a diversified customer base of financial institutions, merchants, corporations, and government agencies with mission-critical technology solutions that enable them to issue, process, and accept transactions securely. Geographically, it operates in Puerto Rico, Caribbean, and Latin America.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.